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Abstract
Alzheimer’s disease (AD), ranked as the seventh leading cause of death world-
wide, is one of the most incidental neurodegenerative disorders. AD patients expe-
rience irreparable damages to the brain, indicated as progressive, insidious, and
degenerative. Past research has discovered that the amyloid cascade hypothesis best
describes the pathophysiological etiology of AD, designating amyloid-β plaques and
neurofibrillary tangles as the ‘hallmarks’ of AD pathology. Furthermore, accumu-
lating evidence show that the oxidative stress state, the imbalance between reactive
oxygen species (ROS) production and antioxidation, contributes to AD develop-
ment. This chapter describes the oxidative stress process in AD. It mainly tackles
the correlation of metal-catalyzed ROS production with amyloid-β and how it
oxidatively damages both the amyloid-β itself and the surrounding molecules,
potentially leading to AD. Additionally, both the role of metal chelation therapy as a
treatment for AD and its challenges will be mentioned as well. This chapter specially
focuses on how metal ions imbalance induces oxidative stress and how it affects AD
pathology.
Keywords: Alzheimer’s disease, Amyloid-β, Reactive oxygen species, Oxidative
stress process, Metal ions, Metal chelation therapy
1. Introduction
Past research has tried to find the pathogenesis and etiologies regarding
Alzheimer’s disease (AD). Recent studies show that reactive oxygen species (ROS)
are linked with the progression and development of AD, especially superoxide
anion, hydrogen peroxide, and hydroxyl radical. Reactive oxygen species have been
found as the by-products of metal-catalyzed oxidation associated with amyloid-β.
These findings are crucial for the treatment of AD, as they provide the underlying
mechanism for metal chelation therapy, which involves the use of metal chelators
for metal removal.
This chapter discusses both past and current research with regards to AD
pathology and treatment in the following order: Alzheimer’s disease, reactive oxy-
gen species, oxidative stress and Alzheimer’s disease, metal chelation therapy, and
challenges of metal chelation therapy.
1
2. Oxidative stress and Alzheimer’s disease
2.1 Alzheimer’s disease
Alzheimer’s disease (AD) is one of the most common neurodegenerative diseases
characterized as insidious, progressive, and degenerative. It accounts for 70% of all
dementia cases in people aged 65 years and older. [1] The World Health Organiza-
tion revealed that AD ranked as the seventh leading cause of death worldwide from
2000 to 2019. Although it is assumed that AD is triggered from genetics, environ-
ment, and dietary factors, the exact causes of AD are still not fully understood. [2]
Patients with AD experience irreversible damage to the brain which leads to
cognitive and behavioral deterioration, shrinkage of brain tissue, and progressive
memory loss. [3] Aβ and NFTs are considered as the two key factors in the
neurodegeneration of AD patients. The forebrain cholinergic neurons are damaged
due to neurofibrillary tangles (NFTs) of P-tau and the accumulation of senile
plaques composed of amyloid-β(AβÞ in the hippocampus, neocortex, amygdala, and
basal nucleus of Meynert. [4]
Although still debated, the amyloid cascade hypothesis best explains the pathol-
ogy of AD. The Aβ protein, a 36 to 43 residue polypeptide (in several studies, 39 to
43 residues/38 to 43 residues), is generated in the process of amyloid precursor
protein (APP) enzymatic proteolysis, a transmembrane protein responsible for
neuron growth and repair. Among the two main pathways for disposal of APP, a
non-amyloidogenicα -secretase-mediated pathway and an amyloidogenic β-and γ
-secretase-mediated pathway, the neuropathology of AD derives from the latter, in
which Aβ peptide is produced. [5]
APP consists of both a cytoplasmic C-terminus and an extracellular
glycosylated N-terminus. In the amyloidogenic pathway, APP is initially cleaved
by a β-secretase creating a membrane bound 99-amino-acid C-terminal fragment.
The C-terminal fragment, now acting as a substrate, is serially cleaved by a γ-
secretase, resulting in a full length Aβ, mainly the 40-amino-acid Aβ40 and the
42-amino-acid Aβ42. [6, 7]
Due to the insolubility in AD patients, the Aβmonomers abnormally aggregate
into higher order assemblies, oligomers, protofibrils, and fibrils, which ultimately
deposit into senile plaques. Amyloid senile plaques spread throughout the brain,
eventuating in the interference of intercellular communication and the activation
of immune cells which provoke inflammation. Neurological brain damage
induced from amyloid plaques are commonly detected in the neocortex of AD
patients. [7, 8]
NFTs, another factor regarded as a key contributor of AD, is linked with Aβ as
well. Microtubules (MTs) in neurons work as directional highways between the
axon and dendrites for organelle transport such as nutrients, neurotransmitters,
motor proteins. The MT arrays also act as architectural elements that stabilize the
structure and shape of the neuron. [9] The firmness of MTs depends on tau, a
microtubule-associated protein (MAP), which plays a vital role in regulating the
dynamic network and assembly of MTs. [10]
There is accumulating evidence that Aβ peptide induces tau hyperpho-
sphorylation, which reduces the MT-tau affinity. Tau, no longer able to bind to
MTs, start to aggregate forming tau clumps. Consequently, due to the decreased
stability, MTs start to disintegrate. Separated tau cluster into tau oligomers, which
eventually develop into neurofibrillary tangles (NFTs). [11] With the breakdown of
the MT system, neurons are incompetent to transmit organelles, resulting in the
neurodegeneration of nerve cells which explains the memory loss and cognitive and
behavioral decline of AD patients.
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2.2 Reactive oxygen species
Reactive oxygen species (ROS) are unstable, highly reactive molecules and rad-
icals which are derived from molecular oxygen. ROS production takes place in
aerobic organisms that utilize mitochondrial electron transport for respiration or
undergo oxidation catalyzed by metals and intracellular enzymes. [12] In normal
settings, ROS play a crucial role for cell signaling such as cell cycle regulation,
enzyme activation and apoptosis. Yet, under oxidative stress conditions, the
immoderate production of ROS has detrimental effects on cells causing protein,
DNA, and lipids damage and eventually, cell death. [1]
When a molecular oxygen goes through a monovalent reduction, superoxide
anion radical (O2 ), a precursor compound of ROS, is formed. [13] O

2 , due to its
unstable state, react with other radicals such as nitric oxide (NOÞ, forming highly
reactive peroxynitrite (ONNO). 02 also propagates further oxidative chain reac-
tions, producing hydrogen peroxide (H2O2Þ with the help of superoxide dismutase
(SOD). H2O2 are sequentially reduced either to hydroxyl radical (OH
), one of the
most reactive oxidants, or fully reduced to water. [14, 15]
ROS generation, mainly in forms of O2 , H2O2, OH
, are induced by both
endogenous and exogenous pathways. The endogenously produced ROS are mainly
byproducts of mitochondrial respiratory chain and phagocytic nicotinamide
adenine dinucleotide phosphate (NADPH) oxidase, circumstances in which the
reduction of oxygen is enabled. [Figures 1 and 2] Transition metals and numerous
intracellular enzymes such as, Xanthine oxidase (XO), Lipoxygenases (LXO), and
Cyclooxygenase (COX) are also principal endogenous ROS generators
(Figures 3–5) [16].
ROS are produced in response to exogenous or environmental factors as well,
such as radiation, air pollutants, diet, tobacco smoke, drugs and xenobiotics, che-
motherapy, and pesticides. [16, 17] Exposure to UVR from solar radiation develops
high concentrations of ROS, which causes an imbalance between ROS and cellular
antioxidants, thus provoking oxidative stress. [17] Tobacco smoke, another notable
factor of ROS production, consists of 1014-1016 free radicals per puff which can
potentially produce H2O2 and OH
. [16]
The right duration, quantity, and location of ROS production is required for
normal physiological processes. In cases where the appropriate conditions are not
met, both insufficient and excessive ROS production, ROS-related diseases can
arise. [15] Such medical conditions include glucolipotoxicity, insulin resistance,
Figure 1.
Amyloidogenicβ -and γ-secretase-mediated pathway of APP disposal In the amyloidogenic pathway of APP
disposal, APP is first cleaved by a β-secretase yielding SAPPβ and CTF99/89. Subsequently, CTF99/89 is
cleaved by a γ-secretase creating AICD and Aβ.
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diabetes mellitus, mitochondrial dysfunction, cancer, autoimmune disorders,
cardiovascular, neurological, and psychiatric disease. [15, 18]
Antioxidants work as the defense mechanism against ROS induced damage. Its
role is to maintain the effective functions of ROS while at the same time, regulate its
level. Oxidative stress is attenuated by both endogenous antioxidant system and the
exogenous intake of antioxidants. [19, 20] The former includes enzymes such as
SOD, glutathione (GSH), catalase and glutathione peroxidase (GPx). [19] Mean-
while, the essential exogenous antioxidants are absorbed through vegetables, whole
grains, fruits, and omega-3 fatty acid containing diet. Vitamin C, vitamin E, β-
carotene, selenium, carotenoids, and polyphenols represent exogenous
antioxidants. [19, 20]
2.3 Oxidative stress and Alzheimer’s disease
Majority of current research show that oxidative stress, the imbalanced state of
ROS production level and antioxidative level, is related to the pathogenesis of neuro-
degenerative diseases, representatively AD. [21] This chapter approaches mainly the
association of oxidative stress with AD, mostly regarding the correlation between Aβ
and ROS production and how it affects the neighboring neural molecules.
As previously stated above in the Alzheimer’s Disease section, amyloid plaques and
NFTs are regarded as the ‘hallmarks’ of AD. Overwhelming evidence show that
amyloid plaques are highly concentrated in metal ions, such as copper Cuð Þ, iron Feð Þ,
Figure 2.
Aβ plaques formation abnormal aggregation ofAβmonomers into oligomers, protofibrils, fibrils, and ultimately
plaques can be seen in AD patients.
Figure 3.
NFTs formation Aβ peptide induces tau hyperphosphorylation, which reduces MT-tau affinity. Separated tau
develop into oligomers and eventually NFTs.
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zinc Znð Þ and calcium Cað Þ, which are present in the synaptic areas. Such metal ions
are interconnected with the amyloid cascade reaction and NFT formation. [22]
Metal ions imbalance induces oxidative stress which triggers ROS production.
Increased production of ROS leads to secretases imbalance and phosphatases
imbalance, each interconnected with the formation of Aβ and P-tau. Accordingly,
Aβ and P-tau production increases, which eventually leads to neurodegenerative
diseases including AD. [23] Thus, the Aβ toxicity, NFTs, oxidative stress, and
ultimately neuronal cell death depend on the existence of redox metals. [24] This
Figure 4.
ROS production pathways endogenous and exogenous pathways of ROS production include mitochondrial






Mitochondrial ROS production complex Iand complex III of the inner mitochondrial membrane create O
2
through oxidative phosphorylation. O
2
, through further reactions, can also yield H2O2, and OH
 .
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chapter mainly discusses the correlation of metal-catalyzed ROS production with
Aβ (Figure 6).
2.3.1 Copper
Among the metal ions, copper is considered the most redox reactive. The asso-
ciation of copper ions with Aβ can be described as a three-step process. First,
endogenous reductants bind with the copper, followed by the reduction of Cu(II) to
Cu(I). The reductive state of copper triggers the reduction of molecular oxygen as
well, producing ROS. [25] Copper directly interacts with Aβ, promoting increased
aggregation of Aβ and the toxicity of amyloid oligomers and plaques. [22, 26]
Histidine His6,His13,His14ð Þ and Tyrosine (Tyr10) amino acid residues modulate
the binding of copper to Aβ:Cu(II) is reduced to Cu(I), after its chemically binding to
Aβ(higher affinity to Aβ1- 42 compared to Aβ1- 40), generating hydrogen peroxide
as a byproduct which has high potential to be reduced to hydroxyl radical. Accord-
ingly, the complexation of copper in Aβ elevates the neurotoxicity, now endowed
with enlarged reduction potential. [24] The Cu- Aβ couple correspondingly assists the
further process of ROS production. The copper- Aβ-mediated oxidation of reductant
species such as ascorbate, which are abundant in the brain, induces generation of
ROS: hydrogen peroxide, hydroxyl radical and superoxide anion. [25]
2.3.2 Iron
Iron, as a redox active metal, is also significantly linked with AD pathology.
However, unlike copper, iron ions do not directly interact with and bind to Aβ. [27]
Figure 6.
Metal ions imbalance, increased ROS production, and neurodegeneration imbalance of metal ions, such as
copper, iron, zinc, and calcium, creates oxidative stress condition. This is followed by increased production of
ROS, and consequently Aβ and NFTs, which eventually provokes neurodegenerative diseases including AD.
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Iron exists in both in redox-inactive forms Fe3þ
 
and redox-active forms Fe2þ
 
within the brain. They are also found in zero-oxidation-state Fe0
 
or as ionic
compounds such as magnetite Fe3O4ð Þ as well. All forms are possible inducers for
Aβ aggregation, prompting the iron redox cycle and ROS production. [28, 29] Iron
concentration and increased free radical production had been noticed in the cere-
bellum and glia cells of AD patients. [23]
After iron’s indirect interaction with Aβ, the redox cycle of Haber-Wiess and
Fenton reaction is triggered, yielding ROS in forms of hydrogen peroxide, hydroxyl
radical and superoxide anion, as in the process of copper-mediated oxidation. The
resulting ROS effects Aβ aggregation and other oxidative damages in local organ-
elles as well. Research results based on high-resolution transmission electron
microscopy (HR-TEM) and synchrotron-based X-ray absorption studies support
the storage of iron within Aβ and the iron-catalyzed ROS production. [27, 29]
During the process of the metal-catalyzed ROS production in correlation with
Aβ, both the Aβ peptide itself and the surrounding molecules undergo oxidative
damages. The amino acid residues of Aβ, cysteine, methionine, arginine, histidine,
lysine, phenylalanine, tryptophan, and tyrosine, are oxidated as well, chemically
changed, and impaired. The ROS produced through metal-mediated oxidation also
cause protein carbonylation and nitration, lipid peroxidation, and protein modifi-
cation. The mitochondria of nearby cells also experience oxidation, leading to
increased mitochondrial and nuclear DNA &RNA damages which all potentially
lead to the etiology of AD. [30]
2.3.3 Zinc
The impact of zinc Zn2þ
 
in AD is rather controversial. [23] Some research
suggests irregularly high concentration of Zn2þ have been investigated in AD
patients’ brains, inferring the linkage between imbalance of Zn2þ homeostasis with
AD pathogenesis. [31] One study indicated that Zn2þ promotes both Aβ40 and Aβ42
aggregation, but only at the early stage. [32] In another study, high concentration of
Zn2þ was shown to induce NADPH-oxidase reaction and ROS production (espe-
cially mitochondrial ROS production) in AD pathological state. Excessive zinc
therefore prompted Aβ cascade reaction. [23] On the contrary, other research




elevation also significantly contributes to Aβ production in AD
patients. Sequentially, increased Aβ level in turn promotes an increase in Cu2þ level
by triggering the opening of voltage-dependent Cu2þ channels. Moreover, high
degree of Cu2þprovokes further influx of Cu2þ by enabling overexpression of
L-type calcium channel subtype (Cav1.2). Excessive Cu2þ consecutively
stimulateAβ production and aggregation. [23]
2.4 Metal chelation therapy, a potential treatment for Alzheimer’s disease
Based on the thesis that AD pathology relates to the interplay between metal ions
and Aβ, treatments for AD have been proposed established on this characteristic.
Metal chelation therapy has been raised as a method to agitate metal- Aβ interac-
tions to treat AD in a lot of research. [27] Metal chelation therapy is initiated by
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injection of chelators (chelating agents) into the bloodstream which bind to the
targeted metals and excrete them. [34]
Studies show that metal chelating agents must satisfy the following conditions to
manipulate as prospective treatments for AD.
1.Low molecular weight
2.Target certain: must be able to selectively attach to targeted metal ions bound
to Aβ
3.Free or poor charge: must be able to cross blood brain barrier (BBB)
4.Low toxicity
5.Low possibility of side effects
Metal chelators content with above properties will successfully affix to aimed
metal ions associated with Aβ, engendering their break-up and removal. [27]
Among the various chelator drugs, only a few are suitable for AD; drugs that
fulfill the properties stated above. The common chelator drugs adopted for AD
treatments that have shown favorable results include desferrioxamine (DFO),
bathophenanthroline, bathocuproine (BC), trientine, penincillamine, bis
(thiosemicarbazone), tetrathiomolybdate (TTM). [35–37]
In one clinical trial in 48 patients with AD, DFO has shown its positive effects.
Using trace-metal analysis, the research team confirmed that DFO decreased the
aluminum level in neocortical brains of AD patients dosed with DFO;125 mg per
injection, twice a day, five days a week. [38] Although it showed outcomes regard-
ing aluminum, one research insisted that, considering the affinity DFO has for iron,
the result might have also been due to the elimination of iron. [39] In addition to
iron, DFO also shows binding affinity towards copper. [40]
Penincillamine, bathophenanthroline, bathocuproine (BC), and trientine have
also been proven to be effective copper chelators. In one research test, these agents
showed interaction with Cu- Aβ couple, deleting copper and improving Aβ solubil-
ity. Furthermore, BC has been proved to be the most efficacious, showing constant
results across the broad range of AD brain tissue samples. [37]
It has been suggested that the bis(thiosemicarbazone) compounds can regulate
the concentration of copper in Aβ as well. [41] In one study, chemical compounds
of the bis(thiosemicarbazone) metal complex family have shown successful treat-
ment for animal models with AD. [42] Similar results have been noticed in another
study using APP/PS1 transgenic AD mice model as well. Bis(thiosemicarbazone)
enhanced the soluble Aβ level by deleting copper and led to the restoration of
cognitive activity. [43]
The effect of tetrathiomolybdate (TTM) as a copper chelator has been demon-
strated as well. In one experiment, TTM was applied to Tg2576 transgenic mice
model for five months. Positive effects were derived, showing that TTM lowered
both the level of Aβ and Aβ plaques present in the brain. [44]
2.5 Challenges of metal chelation therapy
Although the above-stated metal chelating agents have shown positive effects in




First, in addition to the originally aimed effects, metal chelating agents can
induce undesirable outcomes as well. One study revealed that the application of
divalent chelators, such as Cu,Fe and Zn, to severe AD patients lessened the
requisite divalent metals that were already in their appropriate levels, as well as the
targeted metal ions. Accordingly, the depletion of essential metals aggravated rather
than treated AD pathology. [45]
Furthermore, as stated in Metal Chelation Therapy, a Potential Treatment for
Alzheimer’s Disease, metal chelating agents have been proved to lowerAβ level
through solubilization. However, it is still rather controversial whether metal che-
lators can not only solubilize but reverse the Aβ plaques to any forms of intermediates
such as monomers, oligomers, protofibrils, short fibrils, or extended fibrils. [27, 45]
Finally, there are remaining questions concerning the efficacy of certain metal
chelating agents. For instance, clioquinol (CQ), aCu - Zn chelator capable of agitat-
ing Aβ aggregation has been used in numerous clinical trials. However, the clinical
and experimental results show that the effectiveness of CQ is yet contentious.
[45, 46] In one experiment, the utilization of CQ perturbed Cu and Zn homeostasis
which elevated metal ion concentrations, which is contradictory to the predicted
results. CQ also showed side effects, arising astrogliosis, spongiosis, and brain
edema to the mice model. [47]
For further development of metal chelation therapy, such disadvantages should
be improved.
3. Conclusion
Aβ and amyloid plaques are determining symbols of AD. Metal ions, especially
copper and iron, interact with Aβ in AD patient’s brain which generates ROS, such
as superoxide anion, hydrogen peroxide, and hydroxyl radical. This process pro-
motes the aggregation Aβ and increases the toxicity of Aβ plaques. ROS induces
damages to both Aβ itself and the surrounding molecules leading to protein, lipid,
DNA, and RNA impairment. Metal chelation therapy has been proposed as method
to agitate metal- Aβ interactions for AD treatment. Metal chelators injected into
the bloodstream will target metals associated with Aβ and eliminate them,
cutting off the activity of causative substances. The metal chelating agents that have
shown positive effects towards AD so far include desferrioxamine (DFO),
bathophenanthroline, bathocuproine (BC), bis(thiosemicarbazone), tetrathio-
molybdate (TTM), trientine, and penicillamine. However, there are ongoing chal-
lenges facing the metal chelation therapy. The remaining questions regarding the
efficacy of chelating agents and the precise mechanism of chelation therapy should
be solved.
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